Abstract
Multiple myeloma represents malignant transformation of terminally differentiated plasma cells, and makes up 1% of all cancers and 10% of hematological malignancies with a male predominance and higher incidence in older patients. The disease remains incurable with current treatments and contributes to considerable morbidity and mortality among affected patients. The past decade has seen dramatic progress, both in our understanding of the molecular basis of the disease and in the development of new therapies for the disease. The high response rates seen with the new drugs, especially in combination, has led to a paradigm change in the approach to the patient with myeloma.
Original language | English (US) |
---|---|
Title of host publication | Advances in Malignant Hematology |
Publisher | Wiley-Blackwell |
Pages | 315-341 |
Number of pages | 27 |
ISBN (Print) | 9781405196260 |
DOIs | |
State | Published - Mar 24 2011 |
Keywords
- Chromosomal translocations
- Genetics
- Immunoglobulins
- Immunomodulatory drugs
- Monoclonal protein
- Multiple myeloma
- Plasma cell
- Prognosis
- Proteasome inhibitors
- Stem cell transplant
ASJC Scopus subject areas
- General Medicine